• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Click Therapeutics Acquires Better Therapeutics, Expands into Obesity and Cardiometabolic Disease

by Fred Pennic 05/22/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Click Therapeutics, a leader in prescription digital therapeutics (DTx), announced today the acquisition of key assets from Better Therapeutics. 

– Click’s expansion into cardiometabolic disease follows successful DTx development efforts in other areas, including migraine prevention, depression, schizophrenia, and opioid use disorder.  

Strengthening the DTx Pipeline

The acquisition includes several key assets from Better Therapeutics:

  • AspyreRx (BT-001): The first FDA-authorized DTx for type 2 diabetes.
  • BT-004: A DTx with FDA Breakthrough Device Designation for treating metabolic dysfunction-associated steatohepatitis (MASH).
  • BT-002: A DTx designed to reduce blood pressure in patients with hypertension.
  • BT-003: A DTx focused on lowering LDL cholesterol in patients with hyperlipidemia.

The strategic acquisition significantly expands Click’s DTx portfolio, complementing their existing offerings in psychiatry, CNS, and pain management. It also strengthens their position in the rapidly growing market for obesity and cardiometabolic disease treatments.

A Personalized Approach to Weight Management

Click’s existing DTx solutions focus on psychiatry, CNS, and pain disorders. By integrating Better Therapeutics’ assets, Click gains immediate traction in the rapidly growing cardiometabolic space, complementing their current offerings.

Click emphasizes the importance of personalized treatment plans for obesity, a complex chronic disease. Their goal is to develop a best-in-class DTx solution that combines:

  • Behavioral Therapy: Leveraging Better Therapeutics’ clinically validated approach honed over nine years.
  • AI-powered Platform: Click’s platform utilizes advanced engagement techniques and proprietary digital mechanisms to address the disease.
  • Medication Integration: The DTx will be optimized to work seamlessly with anti-obesity and diabetes medications like GLP-1s.

Benefits Beyond Weight Management

This acquisition extends beyond obesity. Click plans to leverage Better Therapeutics’ assets to develop DTx solutions for type 2 diabetes, hypertension, hyperlipidemia, and MASH. This holistic approach positions Click as a leader in DTx solutions for a broad range of cardiometabolic conditions.

“There is immense potential in the cardiometabolic space for next-generation ‘smart’ therapeutics that enhance patient care and provider capabilities,” said Rich DeNunzio, Chief Commercial Officer of Click Therapeutics. “The current one-size-fits-all approach to obesity management can be improved with innovative digital therapeutics that tailor treatments to individual needs, leading to improved patient outcomes and the opportunity to create data-driven contracting models with payers. By collaborating with pharma, payers, providers and patients to layer these capabilities onto the latest drugs, we can transform obesity care and enable our partners to succeed in what is soon to be a highly competitive market.”
  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Healthcare Mergers & Acquisitions

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |